Lanthio Pharma

Groningen, Netherlands Founded: 2010 • Age: 16 yrs Acquired By MorphoSys
Speciality company developing and commercializing therapeutic peptide drugs against difficult to target receptors
Request Access

About Lanthio Pharma

Lanthio Pharma is a company based in Groningen (Netherlands) founded in 2010 was acquired by MorphoSys in May 2015.. Lanthio Pharma has raised $6.27 million across 3 funding rounds from investors including MorphoSys, Rijksdienst voor Ondernemend Nederland and BioGeneration Ventures.

  • Headquarter Groningen, Netherlands
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $6.27 M (USD)

    in 3 rounds

  • Latest Funding Round
    $4.93 M (USD), Debt – Conventional

    May 21, 2014

  • Investors
    MorphoSys

    & 3 more

  • Employee Count
    Employee Count
  • Acquired by
    MorphoSys

    (May 07, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Lanthio Pharma

Lanthio Pharma has successfully raised a total of $6.27M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4.93 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Debt – Conventional — $4.9M
  • First Round
  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2014 Amount Debt – Conventional - Lanthio Pharma Valuation

investors

Nov, 2012 Amount Series A - Lanthio Pharma Valuation BioGeneration Ventures , MorphoSys
Jun, 2011 Amount Seed - Lanthio Pharma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Lanthio Pharma

Lanthio Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include MorphoSys, Rijksdienst voor Ondernemend Nederland and BioGeneration Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Life science focused VC firm investing in startups in Europe
Founded Year Domain Location
AI, deeptech, and healthcare tech companies are funded by Inkef.
Founded Year Domain Location
Provider of subsidies and financial support for businesses
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Lanthio Pharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Lanthio Pharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Lanthio Pharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Lanthio Pharma

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Lanthio Pharma

Frequently Asked Questions about Lanthio Pharma

When was Lanthio Pharma founded?

Lanthio Pharma was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Lanthio Pharma located?

Lanthio Pharma is headquartered in Groningen, Netherlands. It is registered at Groningen, Groningen, Netherlands.

Is Lanthio Pharma a funded company?

Lanthio Pharma is a funded company, having raised a total of $6.27M across 3 funding rounds to date.

What does Lanthio Pharma do?

Lanthio Pharma is committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity. Company is building a growing pipeline of stabilized, receptor specific lanthipeptides with the potential for treatment of fibrosis, heart failure and multiple sclerosis. Pipeline includes LP2 for diabetic nephropathy, lanthi-apelin for heart failure, lanthi-galani for multiple sclerosis and pancyte (indication is confidential). company was acquired by morphosys in 2015.

Who are Lanthio Pharma's investors?

Lanthio Pharma has 4 investors. Key investors include MorphoSys, Rijksdienst voor Ondernemend Nederland, BioGeneration Ventures, and Inkef.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available